Announced partnership with Australian CRO to accelerate initiation of CLD-401 clinical trialThe Company has received feedback from the FDA through Type D interactions, and the Company believes its ...
VERSES AI Inc. (CBOE:VERS) (OTCQB:VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in ...
We are currently living in the age of Ozempic. Millions of people are utilizing these GLP-1 drugs to shed pounds, so much so ...
In modern Crohn’s disease care, the danger of permanent bowel damage usually far outweighs the rare risks associated with targeted biologics.